- Eli Lilly seals a $2.4 billion deal, acquiring Dice Therapeutics to enhance its portfolio of immune-related disease treatments.
- The deal offers a 40% premium on Dice Therapeutics' shares, with closure expected in the third quarter of this year.
- Dice's proprietary technology and its pursuit of new oral drugs for autoimmune diseases are pivotal to this strategic partnership.
In a significant move within the pharmaceutical sector, Eli Lilly, the Indianapolis-based drug manufacturer, announced on Tuesday a strategic acquisition of Dice Therapeutics, a San Francisco-based biopharmaceutical firm. The $2.4 billion deal, aimed at fortifying Eli Lilly's stronghold in treatments for immune-related conditions, is an assertive move toward diversification and expansion.
Eli Lilly is set to pay a noteworthy $48 per share, a roughly 40% premium compared to Dice Therapeutics' closing stock price on the preceding Friday. The market awaits the conclusion of the transaction, projected for the third quarter of this year.
Patrik Jonsson, Eli Lilly's Executive Vice President, emphasized the importance of this partnership. He noted, "The synergy of Dice's innovative technology, drug discovery prowess, and their enthusiastic workforce will significantly bolster our quest to improve the lives of those grappling with debilitating autoimmune diseases."
Dice Therapeutics, with its unique technology platform, paves the way in developing new oral therapeutic drugs to combat autoimmune diseases. In such conditions, the body's immune system erroneously targets its own cells instead of shielding them, often leading to symptoms such as pain, fatigue, dizziness, depression, and rashes.
As it stands, over 100 autoimmune diseases have been identified, spanning from lupus and rheumatoid arthritis to Crohn's disease and ulcerative colitis. Dice is presently conducting a mid-stage trial for their leading drug aimed at managing an immune-related skin disorder known as psoriasis. Meanwhile, Eli Lilly has secured a commanding position in the immunology market with drugs like Taltz, a plaque psoriasis treatment, and Olumiant, a rheumatoid arthritis remedy. Last year alone, Taltz and Olumiant yielded $2.48 billion and $830.5 million in sales, respectively.
WOM Money Picks
Be a part of the winning team | 81% Success Rate.